Hyperlipoproteinemia: genes and variants
Explore variant evidence for Hyperlipoproteinemia across 5 analyzed proteins (LPL, APOA5, APOE, APOC2, HMGCR). Linked ClinVar records include 44 pathogenic or likely pathogenic variants, 32 variants of uncertain significance and 14 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Source labels are pooled across this disease family.
Data updated 2026-11-05. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Hyperlipoproteinemia
LPL: Lipoprotein lipase
It hydrolyzes triglycerides in circulating chylomicrons and very-low-density lipoproteins so tissues can take up released fatty acids. Severe biallelic loss causes familial chylomicronemia, while common variation strongly influences triglyceride levels and cardiovascular risk.
44 ClinVar pathogenic / likely pathogenic and 44 uncertain variants in LPL have source records linked to Hyperlipoproteinemia. Association strength is not clinical gene validity.
APOA5: Apolipoprotein A-V
It strongly modulates plasma triglyceride levels by promoting efficient clearance of triglyceride-rich lipoproteins. Rare loss-of-function variants can cause severe hypertriglyceridemia and increase susceptibility to familial chylomicronemia-like phenotypes and pancreatitis.
0 ClinVar pathogenic / likely pathogenic and 1 uncertain variants in APOA5 have source records linked to Hyperlipoproteinemia. Association strength is not clinical gene validity.
APOE: Apolipoprotein E
It redistributes cholesterol and other lipids between tissues by directing remnant lipoproteins to LDL-receptor-family members. The common epsilon4 isoform strongly increases late-onset Alzheimer disease risk and also influences plasma lipids and cardiovascular risk.
0 ClinVar pathogenic / likely pathogenic and 1 uncertain variants in APOE have source records linked to Hyperlipoproteinemia. Association strength is not clinical gene validity.
APOC2: Apolipoprotein C-II
By activating lipoprotein lipase, it enables hydrolysis of triglycerides in chylomicrons and very-low-density lipoproteins. Biallelic deficiency causes familial chylomicronemia with extreme hypertriglyceridemia and recurrent pancreatitis.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in APOC2 have source records linked to Hyperlipoproteinemia. Association strength is not clinical gene validity.
HMGCR: 3-hydroxy-3-methylglutaryl-coenzyme A reductase
It controls the rate-limiting step of the mevalonate pathway and therefore strongly regulates endogenous cholesterol production. Statins lower LDL cholesterol by inhibiting this activity, causing the liver to increase LDL-receptor-mediated clearance from blood.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in HMGCR have source records linked to Hyperlipoproteinemia. Association strength is not clinical gene validity.
ClinVar pathogenic and likely pathogenic variants linked to Hyperlipoproteinemia
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| LPL G181R | 181 | Pathogenic / likely pathogenic (★★) | |
| LPL G181S | 181 | Pathogenic / likely pathogenic (★★) | |
| LPL R270C | 270 | Pathogenic / likely pathogenic (★★) | |
| LPL H273R | 273 | Pathogenic / likely pathogenic (★★) | |
| LPL D183N | 183 | Pathogenic / likely pathogenic (★★) | |
| LPL R270H | 270 | Pathogenic / likely pathogenic (★★) | |
| LPL L279R | 279 | Pathogenic / likely pathogenic (★★) | |
| LPL G186E | 186 | Pathogenic / likely pathogenic (★★) | |
| LPL C243S | 243 | Essential for determining substrate specificity | Pathogenic / likely pathogenic (★★) |
| LPL H268Y | 268 | Pathogenic / likely pathogenic (★★) | |
| LPL L279V | 279 | Pathogenic / likely pathogenic (★★) | |
| LPL P234L | 234 | Pathogenic / likely pathogenic (★★) | |
| LPL E269K | 269 | Pathogenic / likely pathogenic (★★) | |
| LPL W113R | 113 | Pathogenic / likely pathogenic (★★) | |
| LPL G237D | 237 | Pathogenic / likely pathogenic (★★) | |
| LPL P241S | 241 | Pathogenic / likely pathogenic (★★) | |
| LPL V227A | 227 | Pathogenic / likely pathogenic (★★) | |
| LPL D277N | 277 | Pathogenic / likely pathogenic (★★) | |
| LPL V96L | 96 | Pathogenic / likely pathogenic (★★) | |
| LPL A98T | 98 | Pathogenic / likely pathogenic (★★) | |
| LPL I252T | 252 | Essential for determining substrate specificity | Pathogenic / likely pathogenic (★★) |
| LPL S286G | 286 | Pathogenic / likely pathogenic (★★) | |
| LPL K331E | 331 | Pathogenic / likely pathogenic (★★) | |
| LPL M1I | 1 | Pathogenic / likely pathogenic (★★) | |
| LPL C266Y | 266 | Essential for determining substrate specificity | Pathogenic / likely pathogenic (★) |
| LPL G169E | 169 | Pathogenic / likely pathogenic (★) | |
| LPL S278C | 278 | Pathogenic / likely pathogenic (★) | |
| LPL A203T | 203 | Pathogenic / likely pathogenic (★) | |
| LPL T211K | 211 | Pathogenic / likely pathogenic (★) | |
| LPL S220R | 220 | Pathogenic / likely pathogenic (★) | |
| LPL C310R | 310 | Pathogenic / likely pathogenic (★) | |
| LPL Y289H | 289 | Pathogenic / likely pathogenic (★) | |
| LPL L392V | 392 | PLAT | Pathogenic / likely pathogenic (★) |
| LPL R116Q | 116 | Pathogenic / likely pathogenic (★) | |
| LPL R333C | 333 | Pathogenic / likely pathogenic (★) | |
| LPL D183G | 183 | Pathogenic / likely pathogenic | |
| LPL C266W | 266 | Essential for determining substrate specificity | Pathogenic / likely pathogenic |
| LPL H273P | 273 | Pathogenic / likely pathogenic | |
| LPL S271T | 271 | Pathogenic / likely pathogenic | |
| LPL S199C | 199 | Pathogenic / likely pathogenic | |
| LPL G222E | 222 | Pathogenic / likely pathogenic | |
| LPL D231E | 231 | Pathogenic / likely pathogenic | |
| LPL C445Y | 445 | PLAT | Pathogenic / likely pathogenic |
| LPL R197H | 197 | Pathogenic / likely pathogenic |
Uncertain variants prioritized for review in Hyperlipoproteinemia
| Variant | Position | Protein part | Clinical label | Evidence |
|---|---|---|---|---|
| LPL R116P | 116 | Conflicting reports (★) | +7: 2 other pathogenic changes within 3 positions; R116Q at the same position is pathogenic; seen in 6.6e-06 of gnomAD DNA copies; REVEL 0.813 | |
| LPL H268Q | 268 | Conflicting reports (★) | +7: 7 other pathogenic changes within 3 positions; H268Y at the same position is pathogenic; seen in 6.8e-07 of gnomAD DNA copies; REVEL 0.892 | |
| LPL R333H | 333 | Conflicting reports (★) | +6: 2 other pathogenic changes within 3 positions; R333C at the same position is pathogenic; REVEL 0.795 |
Which prediction tools work for Hyperlipoproteinemia
Observed separation of ClinVar pathogenic / likely pathogenic from benign / likely benign variants (AUROC × 100). This benchmark is not a clinical recommendation.
- EVE: 100 out of 100
- VARITY: 100 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- REVEL: 100 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- CATVariant: 100 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- AlphaMissense: 100 out of 100
- MetaSVM: 99 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaLR: 99 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MutPred: 98 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- CADD: 98 out of 100
- PolyPhen-2: 97 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- phastCons: 95 out of 100
- ESM1b (LLR): 95 out of 100
- phyloP: 92 out of 100
- SIFT: 89 out of 100
- SpliceAI: 60 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- Pangolin: 55 out of 100 (learned from overlapping clinical labels, so this is optimistic)
Same protein, different disease
- Hyperlipidemia, familial combined, LPL related also has ClinVar records linked to LPL variants; they fall partly in the same places as the Hyperlipoproteinemia variants (18 pathogenic / likely pathogenic).
Diseases related to Hyperlipoproteinemia
- Myocardial infarction, also linked to APOA5, APOE, HMGCR and LPL
- Type 2 diabetes mellitus, also linked to APOE, HMGCR and LPL
- Familial hypercholesterolemia, also linked to APOE and HMGCR
- Alzheimer disease, also linked to APOE and HMGCR
- Limb-girdle muscular dystrophy, also linked to HMGCR
- Age related macular degeneration, also linked to APOE
- Diabetes mellitus, also linked to APOE
- Hyperlipidemia, familial combined, LPL related, also linked to LPL
- Parkinson disease, also linked to HMGCR
- Familial type 3 hyperlipoproteinemia, also linked to APOE
- Lewy body dementia, also linked to APOE
- Multiple sclerosis, also linked to HMGCR
Frequently asked questions
Which genes have records linked to Hyperlipoproteinemia?
This view contains 5 analyzed proteins: LPL, APOA5, APOE, APOC2, HMGCR. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 44 pathogenic or likely pathogenic variants, 32 variants of uncertain significance and 14 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 3 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 131 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center